Sharenet Sites 
Sharenet Sites
Trading Statement for the year ended 31 March 2026
CILO CYBIN HOLDINGS LIMITED
Incorporated in the Republic of South Africa
(Registration number 2022/320351/06)
JSE Share code: CCC ISIN: ZAE000310397
Listed on the General Segment of the JSE
Issuer with a weighted voting structure
("Cilo Cybin" or "the Company" or "the Group")
TRADING STATEMENT FOR THE YEAR ENDED 31 MARCH 2026
In terms of the JSE Listings Requirements, companies are required to publish a trading statement as soon as they
become reasonably certain that the financial results for the period to be reported upon next will differ by more than
20% from that of the previous corresponding period. As a result of IFRS 2 share-based listing expenses, explained in
more detail below, shareholders of the Company are advised that the group expects with a reasonable degree of
certainty, to report earnings/(loss) per share ("EPS/LPS") and headline earnings/loss per share ("HEPS/HLPS") for the
year ended 31 March 2026, as set out below:
Year ended Year ended 31 March 2026 *Restated
31 March 2025 Expected 31 March 2025
Reported
EPS/(LPS) (0.85 cents per share) (between 95.88 and 96.05 cents per share) 9.49 cents per share
HEPS/(HLPS) (0.85 cents per share) (between 95.88 and 96.05 cents per share) 9.49 cents per share
*The comparative numbers for 2025 will be restated in terms of IFRS in the annual financial statements for the year
ended 31 March 2026, as a result of reverse acquisition accounting.
The board of directors hereby reminds shareholders that the acquisition of 100% of Cilo Cybin Pharmaceutical's ("CC
Pharmaceutical") share capital was concluded on 29 September 2025 and settled through the issue of Cilo Cybin
Holdings Limited shares.
The acquisition was a reverse acquisition in terms of IFRS, resulting in CC Pharmaceutical being deemed the
accounting acquirer and the Company the accounting acquiree, since Cilo Cybin did not meet the definition of a
"business" in terms of IFRS 3. Accordingly, any excess of the fair value of the shares issued by the accounting acquirer
over the fair value of the accounting acquiree's recognisable net assets was expensed, since the excess fair value
represents a share-based payment made in exchange for obtaining a listing. This resulted in the group having to
recognise a once off IFRS 2 share-based payment/ listing expense in the Statement of Profit and Loss
of R217 480 665.
The financial information on which this trading statement is based is the responsibility of the Board and has not been
reviewed or reported on by the Group's independent auditors. The annual results are expected to be released on SENS
on or about Friday, 28 August 2026.
Directors:
Executive
Gabriel Christiaan Theron (Chief Executive Officer)
Jessica Moodley Theron (Acting Chief Financial Officer)
Non-executive
Sakekile Baduza* (Lead Independent Director)
Dr Tham Seng Kong (Chairman)
Daktuk Mohd Razef Abdullah*
Hendrik Jacobus (Henk) Vivier*
* Independent
Registered office
The registered office, which is also the principal place of business, is:
23 Sterling Road, Unit E4 The Point Office Park, Samrand, 0157
Centurion
12 August 2026
Sponsor
Merchantec Capital
Date: 12-08-2026 04:25:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
